NCT07217028View on ClinicalTrials.gov

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

November 30, 2029

Study Completion Date

April 30, 2031

Conditions
SCC - Squamous Cell CarcinomaRadiotracerHead and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Cetuximab (EGFR inhibitor)

Given IV

DRUG

18F-NOTA-ABY-030

Given Bolus Injection

PROCEDURE

Positron Emission Tomography (PET)

Undergo PET/CT

Trial Locations (1)

37232

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Vanderbilt-Ingram Cancer Center

OTHER